Interim analysis from the IMPACT study shows that after four screening rounds (annual PSA) for men aged 55-69 with cancer-predisposing BRCA2 variants, you would expect to detect one clinically significant prostate cancer for every 13 men screened(23). The gene discussed is BRCA2; the disease is cancer.